name: Liver Cirrhosis
category: Complex
parents:
- Hepatic Disease
disease_term:
  preferred_term: cirrhosis of liver
  term:
    id: MONDO:0005155
    label: cirrhosis of liver
has_subtypes:
- name: Alcoholic Cirrhosis
  description: Cirrhosis due to chronic alcohol abuse.
- name: Viral Cirrhosis
  description: Cirrhosis from chronic hepatitis B or C infection.
- name: Non-Alcoholic Steatohepatitis Cirrhosis
  description: Cirrhosis from metabolic-associated fatty liver disease.
- name: Primary Biliary Cholangitis
  description: Autoimmune destruction of intrahepatic bile ducts.
- name: Primary Sclerosing Cholangitis
  description: Chronic inflammation and fibrosis of bile ducts.
pathophysiology:
- name: Hepatocyte Injury and Death
  description: >
    Chronic liver injury from any cause leads to ongoing hepatocyte death,
    triggering inflammation and regenerative responses that promote fibrosis.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:39063116
    supports: SUPPORT
    snippet: "Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality."
    explanation: This review establishes that chronic liver injury is the initiating event leading to inflammation and fibrosis in cirrhosis development.
- name: Hepatic Stellate Cell Activation
  description: >
    Quiescent stellate cells transform into myofibroblasts, producing
    excessive collagen and extracellular matrix. This is the central
    event in liver fibrosis.
  cell_types:
  - preferred_term: Hepatic Stellate Cell
    term:
      id: CL:0000632
      label: hepatic stellate cell
  biological_processes:
  - preferred_term: Extracellular Matrix Deposition
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:39063116
    supports: SUPPORT
    snippet: "LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate Î±-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis."
    explanation: This review definitively establishes HSC activation and transdifferentiation into myofibroblasts as the central mechanism of liver fibrosis and cirrhosis.
  - reference: PMID:39063116
    supports: SUPPORT
    snippet: "The accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival."
    explanation: Macrophages play a key role in initiating and maintaining HSC activation, linking hepatocyte injury to stellate cell-mediated fibrosis.
- name: Portal Hypertension
  description: >
    Increased resistance to portal blood flow due to architectural
    distortion and nodule formation. Leads to varices, ascites, and
    splenomegaly.
  cell_types:
  - preferred_term: Endothelial Cell of Hepatic Sinusoid
    term:
      id: CL:1000398
      label: endothelial cell of hepatic sinusoid
  evidence:
  - reference: PMID:38642564
    supports: SUPPORT
    snippet: "Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy. Portal hypertension occurs due to increased resistance of the cirrhotic liver vasculature to portal blood flow and is further aggravated by the hyperdynamic circulatory syndrome."
    explanation: This comprehensive review establishes portal hypertension as the primary complication of cirrhosis, caused by increased intrahepatic vascular resistance and leading to major clinical complications.
  - reference: PMID:38642564
    supports: SUPPORT
    snippet: "Existing knowledge indicates that the profibrogenic phenotype acquired by sinusoidal cells is the initial factor leading to increased hepatic vascular tone and fibrosis, which cause increased vascular resistance and portal hypertension."
    explanation: This identifies the cellular mechanism by which sinusoidal cell dysfunction increases vascular resistance and drives portal hypertension development.
  - reference: PMID:38534382
    supports: SUPPORT
    snippet: "Liver cirrhosis leads to portal hypertension (PH) with capillarization of liver sinusoidal endothelial cells (LSECs), although drug treatment options for PH are currently limited."
    explanation: This study demonstrates that LSEC capillarization is a key pathological mechanism contributing to portal hypertension in cirrhosis.
  - reference: PMID:38534382
    supports: SUPPORT
    snippet: "Tofogliflozin prevented PH with attenuated intrahepatic vasoconstriction, sinusoidal capillarization, and remodeling independent of glycemic status in CCl4-treated rats."
    explanation: This experimental study demonstrates that preventing LSEC capillarization reduces portal hypertension, confirming the causal role of sinusoidal remodeling in PH development.
- name: Synthetic Dysfunction
  description: >
    Reduced hepatocyte mass impairs production of clotting factors,
    albumin, and other proteins, leading to coagulopathy and hypoalbuminemia.
  biological_processes:
  - preferred_term: Protein Synthesis
    term:
      id: GO:0006412
      label: translation
  evidence:
  - reference: PMID:39063116
    supports: SUPPORT
    snippet: "Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells."
    explanation: While addressing fibrosis reversibility, this demonstrates that loss of functional hepatocyte mass drives cirrhosis complications, and restoration depends on eliminating ongoing injury.
phenotypes:
- name: Ascites
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Fluid accumulation in peritoneal cavity
  phenotype_term:
    preferred_term: Ascites
    term:
      id: HP:0001541
      label: Ascites
  evidence:
  - reference: PMID:38642564
    supports: SUPPORT
    snippet: "Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy."
    explanation: This establishes ascites as one of the major life-threatening complications arising from portal hypertension in cirrhosis.
- name: Jaundice
  category: Hepatic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
- name: Hepatomegaly
  category: Hepatic
  frequency: FREQUENT
  notes: May become shrunken in advanced disease
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- name: Splenomegaly
  category: Hepatic
  frequency: FREQUENT
  notes: Due to portal hypertension
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  evidence:
  - reference: PMID:38642564
    supports: SUPPORT
    snippet: "Portal hypertension occurs due to increased resistance of the cirrhotic liver vasculature to portal blood flow and is further aggravated by the hyperdynamic circulatory syndrome."
    explanation: Splenomegaly results from portal hypertension and the hyperdynamic circulatory changes in cirrhosis, leading to splenic congestion.
- name: Coagulopathy
  category: Hematologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Coagulopathy
    term:
      id: HP:0003256
      label: Abnormality of the coagulation cascade
- name: Hepatic Encephalopathy
  category: Neurological
  frequency: OCCASIONAL
  notes: Confusion due to ammonia accumulation
  phenotype_term:
    preferred_term: Hepatic Encephalopathy
    term:
      id: HP:0002480
      label: Hepatic encephalopathy
  evidence:
  - reference: PMID:38642564
    supports: SUPPORT
    snippet: "Portal hypertension represents the primary non-neoplastic complication of liver cirrhosis and has life-threatening consequences, such as oesophageal variceal bleeding, ascites, and hepatic encephalopathy."
    explanation: This establishes hepatic encephalopathy as one of the major life-threatening complications of portal hypertension in cirrhosis.
- name: Fatigue
  category: Systemic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
biochemical:
- name: Albumin
  presence: Decreased
  context: Reflects synthetic function
- name: Bilirubin
  presence: Elevated
  context: Impaired conjugation and excretion
- name: Prothrombin Time/INR
  presence: Elevated
  context: Coagulation factor deficiency
- name: Ammonia
  presence: Elevated
  context: Associated with encephalopathy
- name: Transaminases
  presence: Elevated
  context: May be normal in advanced cirrhosis
genetic:
- name: HFE
  association: Causative
  notes: Hereditary hemochromatosis
- name: ATP7B
  association: Causative
  notes: Wilson disease
- name: SERPINA1
  association: Causative
  notes: Alpha-1 antitrypsin deficiency
environmental:
- name: Alcohol
  notes: Major cause worldwide
- name: Hepatitis B/C Virus
  notes: Leading causes of viral cirrhosis
- name: Obesity/Metabolic Syndrome
  notes: Driving NASH cirrhosis epidemic
- name: Hepatotoxic Drugs
  notes: Including acetaminophen overdose
treatments:
- name: Alcohol Abstinence
  description: Essential for alcoholic cirrhosis.
  treatment_term:
    preferred_term: alcohol intake avoidance
    term:
      id: MAXO:0010050
      label: alcohol intake avoidance
- name: Antiviral Therapy
  description: Curative for hepatitis C, suppressive for hepatitis B.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: MAXO:0000168
      label: antiviral agent therapy
- name: Diuretics
  description: Spironolactone and furosemide for ascites management.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Beta Blockers
  description: Non-selective beta blockers prevent variceal bleeding.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lactulose
  description: Treats and prevents hepatic encephalopathy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Rifaximin
  description: Antibiotic for hepatic encephalopathy prophylaxis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Liver Transplantation
  description: Definitive treatment for decompensated cirrhosis.
  treatment_term:
    preferred_term: liver transplantation
    term:
      id: MAXO:0001175
      label: liver transplantation
- name: Hepatocellular Carcinoma Surveillance
  description: Regular ultrasound screening.
  treatment_term:
    preferred_term: cancer screening
    term:
      id: MAXO:0000126
      label: cancer screening
datasets:
# Liver Cirrhosis Gut Microbiome Studies (Gut-Liver Axis)
- accession: sra:PRJNA471972
  title: Italian cohort cirrhosis metagenomics
  description: >-
    Shotgun metagenomics from Italian cirrhosis cohort examining gut-liver
    axis dysfunction. Contributes to universal microbiome signature for
    cirrhosis detection.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - liver cirrhosis
    - healthy controls
  notes: Cell Metabolism 2020 - universal cirrhosis signature

- accession: sra:PRJNA647523
  title: Gut microbiome in NAFLD-related hepatocellular carcinoma
  description: >-
    Metagenomic sequencing examining gut microbiota impact on peripheral
    immune response in NAFLD-related hepatocellular carcinoma patients
    with underlying cirrhosis.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - NAFLD-related HCC
    - NAFLD cirrhosis without HCC
    - healthy controls
  publication: PMID:33384396
  notes: Nature Communications 2021 - cirrhosis to HCC progression

- accession: sra:PRJNA328258
  title: Gut microbiome in pediatric NAFLD
  description: >-
    Shotgun metagenomics examining bacterial species and metabolic pathways
    associated with NAFLD in obese youth, representing early-stage liver
    disease progression toward fibrosis.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  sample_count: 36
  conditions:
    - NAFLD
    - obese without NAFLD
    - healthy controls
  publication: PMID:35344283
  notes: Hepatology Communications 2022
